Coupled with its co-localization with hypoxia markers in mouse xenograft tumors and PDX prostate cancer models, our findings suggest that GLUT3 should be included in a panel of endogenous biomarkers of hypoxia for further clinical investigation. This evidence concerns the gene SLC2A3 and prostate carcinoma.